Chester County News and Community Website
YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced its financial results for the year and quarter ending December 31, 2024, spotlighting strong growth in XHANCE prescriptions and revenue. The company also …
Optinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational Income Read More YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth quarter of 2024, driven by sustained growth in prescriptions for XHANCE® (fluticasone …
Optinose Reports $22.4 Million in Preliminary Q4 Revenue for XHANCE Read More YARDLEY, PA — Optinose, Inc. (NASDAQ: OPTN) has announced a 1-for-15 reverse stock split, set to take effect on December 30, 2024, at 5:00 p.m. Eastern Time. Starting December 31, …
Optinose Announces 1-for-15 Reverse Stock Split Read More YARDLEY, PA — Optinose (NASDAQ: OPTN) has released its financial results for the third quarter of 2024, revealing an increase in net revenue from its flagship product, XHANCE, and adjustments …
Optinose Reports Q3 2024 Financial Results, Highlights XHANCE Performance Read More YARDLEY, PA — Optinose, Inc. (NASDAQ: OPTN) has announced the allocation of non-qualified stock option awards to eight newly hired employees as part of their recruitment strategy. This move is designed …
Optinose Grants Stock Options to Attract New Talent Read More YARDLEY, PA — Optinose (NASDAQ:OPTN) has appointed Terry Kohler as its new Chief Financial Officer, a strategic addition to the company’s executive team aimed at driving financial leadership and growth. Kohler …
Optinose Appoints Terry Kohler as Chief Financial Officer Read More YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced the publication of a paper in the International Forum of Allergy & Rhinology, shedding light on the effectiveness of EDS-FLU (XHANCE) in treating …
New Study Highlights XHANCE’s Efficacy in Treating Chronic Rhinosinusitis Read More YARDLEY, PA — Optinose (NASDAQ: OPTN) has released its financial results for the quarter ending June 30, 2024, along with key operational updates.
Optinose Reports Q2 2024 Financial Results and Operational Highlights Read More YARDLEY, PA — Optinose (NASDAQ: OPTN) announced this week that its drug XHANCE® (fluticasone propionate) has been added to Express Scripts’ national formularies. These include the National Preferred, Flex, and …
Optinose’s XHANCE Added to Express Scripts’ National Formularies Read More YARDLEY, PA — Optinose (NASDAQ: OPTN), a specialty pharmaceutical company, announced its financial results for the first quarter of 2024, showcasing a strong performance with a notable increase in revenue …
Optinose Reports Growth in Q1 and Optimistic Outlook for XHANCE Read More